You are here

Company Monitoring Page for Biocon

latest headlines for company on cafepharma

Biosimilar uptake appears to finally be on the upswing, and Biocon Biologics is betting on the sector’s future

Pharma Voice

Tue, 04/9/24 - 05:45 pm

Tags:

biosimilars, Biocon

Biosimilar makers split strategies in bid to take on top-selling Humira

BioPharma Dive

Thu, 07/27/23 - 10:25 am

Tags:

biosimilars, Humira, AbbVie, rebates, drug pricing, Amgen, Celltrion, Novartis, Boehringer Ingelheim, Biocon, Fresenius, Sandoz, Organon, Coherus

7 companies are rolling out Humira biosimilars

Drugstore News

Wed, 07/12/23 - 09:44 am

Tags:

AbbVie, Humira, biosimilars, Boehringer Ingelheim, Organon, Samsung Bioepsis, Sandoz, Fresenius Kabi, Celltrion, Coherus Biosciences, Biocon

FDA rejects Biocon and Viatris' Avastin biosimilar after inspection question marks

Endpoints

Mon, 02/13/23 - 10:02 pm

Tags:

FDA, Biocon, Viatris, Avastin, biosimilars, drug manufacturing

Takeover-driven resurgence fails to materialize for biotech

EP Vantage

Thu, 04/14/22 - 10:41 am

Tags:

M&A, AbbVie, Biocon, Biogen, Biohaven, GSK, Halozyme Therapeutics, Samsung Bioepis, UCB, Viatris

Biocon buys Viatris biosimilars for $3.3bn, eyes IPO

Pharmaforum

Mon, 02/28/22 - 09:20 am

Tags:

Biocon, India, Viatris, Mylan, biosimilars, M&A

Viatris launched two versions of its interchangeable insulin biosimilar. Why?

Fierce Pharma

Tue, 11/16/21 - 10:29 pm

Tags:

Biocon, Viatris, Semglee, insulin, biosimilars, diabetes, Sanofi, Lantus

How This Historic FDA Approval Benefits Viatris

Motley Fool

Wed, 08/4/21 - 10:57 am

Tags:

Viatris, Biocon, FDA, Semglee, biosimilars, insulin, diabetes, interchangeable biosimilars

Biocon and Mylan Launch Semglee; Biosimilar, Interchangeable Status Are Sought

Center for Biosimilars

Tue, 09/1/20 - 10:44 am

Tags:

Biocon, Mylan, Semglee, generics, insulin, diabetes, biosimilars

Mylan and Biocon Gain FDA Approval for Insulin Equivalent to Sanofi's Lantus

Motley Fool

Fri, 06/12/20 - 08:03 pm

Tags:

FDA, Mylan, Biocon, Semglee, Sanofi, insulin, Lantus, diabetes

Biocon insulin operation gets FDA nod, paving way for approval of Lantus knockoff

Fierce Pharma

Thu, 04/2/20 - 11:58 pm

Tags:

Biocon, insulin, diabetes, Lantus, Mylan, drug manufacturing

Mylan's Lantus copy derailed in U.S. again by manufacturing ills

Fierce Pharma

Tue, 09/3/19 - 10:24 am

Tags:

Mylan, Lantus, generics, Biocon, drug manufacturing, diabetes

With FDA spanking, Biocon and Mylan face new hurdle for Lantus challenger

Fierce Pharma

Mon, 07/8/19 - 10:18 pm

Tags:

FDA, Biocon, Mylan, Sanofi, Lantus, insulin, drug manufacturing

Merck ditches biosimilar Lantus, but will that ease the path for Mylan’s rival insulin product?

Fierce Pharma

Fri, 10/12/18 - 12:47 pm

Tags:

Merck, Samsung Bioepis, Lantus, insulin, diabetes, biosimilars, Mylan Labs, Biocon

Coherus BioSciences Re-Submits BLA for Neulasta (Pegfilgrastim) Biosimilar Candidate

CP Wire

Thu, 05/3/18 - 11:11 pm

Tags:

Coherus Biosciences, Neulasta, CHS-1701, Mylan, Biocon

Thu, 05/3/18 - 02:45 pm

Tags:

Coherus Biosciences, Neulasta, CHS-1701, Mylan, Biocon

Novartis ties a new round of biosimilar development programs to a partnership deal with India’s Biocon

Endpoints

Thu, 01/18/18 - 10:35 pm

Tags:

Novartis, Biocon, drug development, biosimilars

FDA Approves Eighth Biosimilar, First for Cancer Drug Herceptin

RAPS.org

Sat, 12/2/17 - 11:20 am

Tags:

FDA, biosimilars, Herceptin, Ogivri, Mylan Labs, Biocon

Biocon and Mylan say their plant is good to go as FDA decision nears for their Herceptin copy

Fierce Pharma

Tue, 11/21/17 - 11:42 am

Tags:

Biocon, Mylan Labs, FDA, Herceptin, drug manufacturing, biologics, India

Mylan and Biocon biosimilar of Amgen’s Neulasta hit with manufacturing-related CRL

Fierce Pharma

Tue, 10/10/17 - 10:18 am

Tags:

Mylan Labs, Biocon, Amgen, Neulasta, CRL, FDA, biosimilars

Pages

last 30 twitter posts